[go: up one dir, main page]

EP1178800A4 - Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease - Google Patents

Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease

Info

Publication number
EP1178800A4
EP1178800A4 EP00916643A EP00916643A EP1178800A4 EP 1178800 A4 EP1178800 A4 EP 1178800A4 EP 00916643 A EP00916643 A EP 00916643A EP 00916643 A EP00916643 A EP 00916643A EP 1178800 A4 EP1178800 A4 EP 1178800A4
Authority
EP
European Patent Office
Prior art keywords
treatment
protease inhibitors
neurodegenerative diseases
aspartyl protease
aspartyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP00916643A
Other languages
German (de)
English (en)
Other versions
EP1178800A1 (fr
Inventor
Jonathan A Ellman
Gary Lynch
Irwin D Kuntz
Xiaoning Bi
Christina E Lee
A Geoffrey Skillman
Tasir Haque
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California Berkeley
University of California San Diego UCSD
Original Assignee
University of California Berkeley
University of California San Diego UCSD
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California Berkeley, University of California San Diego UCSD filed Critical University of California Berkeley
Publication of EP1178800A1 publication Critical patent/EP1178800A1/fr
Publication of EP1178800A4 publication Critical patent/EP1178800A4/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Indole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
EP00916643A 1999-03-24 2000-03-24 Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease Withdrawn EP1178800A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12595899P 1999-03-24 1999-03-24
US125958P 1999-03-24
PCT/US2000/007804 WO2000056335A1 (fr) 1999-03-24 2000-03-24 Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease

Publications (2)

Publication Number Publication Date
EP1178800A1 EP1178800A1 (fr) 2002-02-13
EP1178800A4 true EP1178800A4 (fr) 2002-07-31

Family

ID=22422250

Family Applications (1)

Application Number Title Priority Date Filing Date
EP00916643A Withdrawn EP1178800A4 (fr) 1999-03-24 2000-03-24 Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease

Country Status (5)

Country Link
EP (1) EP1178800A4 (fr)
JP (1) JP2002539260A (fr)
AU (1) AU3771700A (fr)
CA (1) CA2367112A1 (fr)
WO (1) WO2000056335A1 (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1787984T3 (en) 2000-03-06 2017-01-30 Acadia Pharm Inc AZACYCLIC COMPOUNDS FOR USING THE TREATMENT OF SEROTON-RELATED DISEASES
EP1265849B1 (fr) 2000-03-23 2006-10-25 Elan Pharmaceuticals, Inc. Composes et methodes de traitement de la maladie d'alzheimer
PE20020276A1 (es) 2000-06-30 2002-04-06 Elan Pharm Inc COMPUESTOS DE AMINA SUSTITUIDA COMO INHIBIDORES DE ß-SECRETASA PARA EL TRATAMIENTO DE ALZHEIMER
CA2410972A1 (fr) 2000-06-30 2002-01-10 Elan Pharmaceuticals, Inc. Composes pour traiter la maladie d'alzheimer
US6846813B2 (en) 2000-06-30 2005-01-25 Pharmacia & Upjohn Company Compounds to treat alzheimer's disease
EP1666452A2 (fr) 2000-06-30 2006-06-07 Elan Pharmaceuticals, Inc. Composés pour le traitement de la maladie d'Alzheimer
US6696488B2 (en) 2000-08-11 2004-02-24 The Brigham And Women's Hospital, Inc. (Hydroxyethyl)ureas as inhibitors of alzheimer's β-amyloid production
CA2448834A1 (fr) * 2001-06-01 2002-12-12 Elan Pharmaceuticals, Inc. Derives d'hydroxyalkylamines comme inhibiteurs de beta-secratase et leurs utilisations pour le traitement de la maladie d'alzheimer et de maladies similaires
BR0210721A (pt) 2001-06-27 2004-07-20 Elan Pharm Inc Composto, sal ou éster farmaceuticamente aceitável, método para fabricar um composto, e, método para tratar um paciente que tem, ou para evitar que o paciente adquira uma doença ou condição
WO2003029169A2 (fr) * 2001-10-04 2003-04-10 Elan Pharmaceuticals, Inc. Hydroxypropylamines
AU2002360508A1 (en) 2001-12-06 2003-06-23 Elan Pharmaceuticals, Inc. Substituted hydroxyethylamines
BR0215429A (pt) 2001-12-28 2004-12-14 Acadia Pharm Inc Composto de fórmula i e seus usos, métodos de inibição da atividade e método de inibição da ativação de um receptor de monoamina, métodos de tratamento, método de identificação de polimorfismo genético e método de identificação de paciente
AU2003303141A1 (en) 2002-04-30 2004-07-22 Elan Pharmaceuticals, Inc. Hydroxypropyl amides for the treatment of alzheimer's disease
CA2489095A1 (fr) * 2002-06-17 2003-12-24 Sunesis Pharmaceuticals, Inc. Inhibiteurs de l'aspartyl-protease
US7115652B2 (en) 2002-06-17 2006-10-03 Sunesis Pharmaceuticals, Inc. Aspartyl protease inhibitors
US7253186B2 (en) 2002-06-24 2007-08-07 Carl-Magnus Andersson N-substituted piperidine derivatives as serotonin receptor agents
AU2003247615B2 (en) 2002-06-24 2007-08-09 Acadia Pharmaceuticals Inc. N-substituted piperidine derivatives as serotonin receptor agents
US7538222B2 (en) 2002-06-24 2009-05-26 Acadia Pharmaceuticals, Inc. N-substituted piperidine derivatives as serotonin receptor agents
SG170617A1 (en) 2003-01-16 2011-05-30 Acadia Pharm Inc Selective serotonin 2a/2c receptor inverse agonists as therapeutics for neurodegenerative diseases
AU2003297826A1 (en) * 2003-06-16 2005-01-28 Sunesis Pharmaceuticals, Inc Aspartyl protease inhibitors
CA2534672A1 (fr) 2003-08-08 2005-02-17 Schering Corporation Inhibiteurs d'amines cycliques bace-1 renfermant un substituant heterocyclique
US20050261278A1 (en) 2004-05-21 2005-11-24 Weiner David M Selective serotonin receptor inverse agonists as therapeutics for disease
US7820695B2 (en) 2004-05-21 2010-10-26 Acadia Pharmaceuticals, Inc. Selective serotonin receptor inverse agonists as therapeutics for disease
US7790899B2 (en) 2004-09-27 2010-09-07 Acadia Pharmaceuticals, Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N′-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
AU2005289444B2 (en) 2004-09-27 2012-06-14 Acadia Pharmaceuticals Inc. Synthesis of N-(4-fluorobenzyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl)carbamide and its tartrate salt and crystalline forms
PL2134330T3 (pl) 2007-03-19 2013-10-31 Acadia Pharm Inc Kombinacje odwrotnych agonistów i antagonistów 5-HT2A z antypsychotykami
WO2009129532A1 (fr) 2008-04-18 2009-10-22 University Of Connecticut Composés pour modulation lysosomale et procédés d’utilisation
PT3325444T (pt) 2015-07-20 2021-09-22 Acadia Pharm Inc Métodos para preparar n-(4-fluorobenzil)-n-(1-metilpiperidina-4-il)-n'-(4-(2-metilpropiloxi)fenilmetil)carbamida e o seu sal de tartarato e forma polimórfica c
US10953000B2 (en) 2016-03-25 2021-03-23 Acadia Pharmaceuticals Inc. Combination of pimavanserin and cytochrome P450 modulators
WO2017165635A1 (fr) 2016-03-25 2017-09-28 Acadia Pharmaceuticals Inc. Association de pimavansérine et de modulateurs du cytochrome p450
EP3558311A1 (fr) 2016-12-20 2019-10-30 Acadia Pharmaceuticals Inc. Pimavansérine seule ou en association pour une utilisation dans le traitement de la psychose liée à la maladie d'alzheimer
EP3615028A1 (fr) 2017-04-28 2020-03-04 Acadia Pharmaceuticals Inc. Pimavansérine pour le traitement d'un trouble de contrôle des impulsions
EP3675827A1 (fr) 2017-08-30 2020-07-08 Acadia Pharmaceuticals Inc. Formulations de pimavansérine
CN113164563A (zh) * 2018-07-23 2021-07-23 因柯利尔疗法公司 神经性病症的治疗方法
CN113164557A (zh) 2018-07-23 2021-07-23 因柯利尔疗法公司 治疗神经性病症的方法
AU2020271894A1 (en) 2019-04-11 2021-12-02 Enclear Therapies, Inc. Methods of amelioration of cerebrospinal fluid and devices and systems therefor
US20220096745A1 (en) 2020-09-29 2022-03-31 Enclear Therapies, Inc. Subarachnoid fluid conduit system and kit

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033795A1 (fr) * 1997-02-04 1998-08-06 The Regents Of The University Of California Inhibiteurs de cathepsine d nanomolaires et non peptidiques

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998033795A1 (fr) * 1997-02-04 1998-08-06 The Regents Of The University Of California Inhibiteurs de cathepsine d nanomolaires et non peptidiques

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
CATALDO A M ET AL: "ENZYMATICALLY ACTIVE LYSOSOMAL PROTEASES ARE ASSOCIATED WITH AMYLOID DEPOSITS IN ALZHEIMER BRAIN", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 87, no. 10, 1 May 1990 (1990-05-01), pages 3861 - 3865, XP000602294, ISSN: 0027-8424 *
CATALDO A M ET AL: "LYSOSOMAL HYDROLASES OF DIFFERENT CLASSES ARE ABNORMALLY DISTRIBUTED IN BRAINS OF PATIENTS WITH ALZHEIMER DISEASE", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, NATIONAL ACADEMY OF SCIENCE. WASHINGTON, US, vol. 88, December 1991 (1991-12-01), pages 10998 - 11002, XP002929850, ISSN: 0027-8424 *
CATALDO A M ET AL: "LYSOSOMAL PROTEINASE ANTIGENS ARE PROMINENTLY LOCALIZED WITHIN SENILE PLAQUES OF ALZHEIMER'S DISEASE EVIDENCE FOR A NEURONAL ORIGIN", BRAIN RESEARCH, vol. 513, no. 2, 1990, pages 181 - 192, XP001070394, ISSN: 0006-8993 *
CATALDO ANNE M ET AL: "Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer's disease and Down's syndrome.", JOURNAL OF NEUROPATHOLOGY & EXPERIMENTAL NEUROLOGY, vol. 55, no. 6, 1996, pages 704 - 715, XP001070366, ISSN: 0022-3069 *
HAQUE, TASIR S. ET AL: "Potent, Low-Molecular-Weight Non-Peptide Inhibitors of Malarial Aspartyl Protease Plasmepsin II", J. MED. CHEM. (1999), 42(8), 1428-1440, XP000926504 *
KENESSEY AGNES ET AL: "Degradation of tau by lysosomal enzyme cathepsin D: Implication for Alzheimer neurofibrillary degeneration.", JOURNAL OF NEUROCHEMISTRY, vol. 69, no. 5, 1997, pages 2026 - 2038, XP001069801, ISSN: 0022-3042 *
KREUTZBERG G W: "Microglia, the first line of defence in brain pathologies.", ARZNEIMITTEL-FORSCHUNG, vol. 45, no. 3A, 1995, pages 357 - 360, XP001068957, ISSN: 0004-4172 *
LEE, CHRISTINA E. ET AL: "General solid-phase synthesis approach to prepare mechanism-based aspartyl protease inhibitor libraries. Identification of potent cathepsin D inhibitors", J. AM. CHEM. SOC. (1998), 120(38), 9735-9747, XP002197748 *
LI K ET AL: "ABNORMAL DISTRIBUTION OF CATHEPSIN PROTEINASES AND ENDOGENOUS INHIBITORS (CYSTATINS) IN THE HIPPOCAMPUS OF PATIENTS WITH ALZHEIMER'S DISEASE, PARKINSONISM-DEMENTIA COMPLEX ON GUAM, AND SENILE DEMENTIA AND IN THE AGED", VIRCHOWS ARCHIV A. PATHOLOGICAL ANATOMY AND HISTOPATHOLOGY, SPRINGER VERLAG, BERLIN, DE, vol. 423, no. 3, 1 September 1993 (1993-09-01), pages 185 - 194, XP002062087, ISSN: 0174-7398 *
See also references of WO0056335A1 *

Also Published As

Publication number Publication date
EP1178800A1 (fr) 2002-02-13
AU3771700A (en) 2000-10-09
CA2367112A1 (fr) 2000-09-28
JP2002539260A (ja) 2002-11-19
WO2000056335A1 (fr) 2000-09-28

Similar Documents

Publication Publication Date Title
EP1178800A4 (fr) Traitement des maladies neurodegeneratives par des inhibiteurs de l'aspartyl protease
IL138628A0 (en) Treatment of parasitic diseases by inhibition of cyteine proteases of the papain superfamily
DE60124302D1 (de) Thiazolderivate zur behandlung von ppar-lierte krankheiten
ATE269866T1 (de) Intranasale zubereitungen zur behandlung sexueller störungen
FR12C0077I2 (fr) Composition pour le traitement des condylomes génitaux
ATE434444T1 (de) Vorbeugung und behandlung von amyloidogenischen krankheiten
ES2191102T3 (es) Heterociclos de peptidilo utiles en el tratamiento de las afecciones relacionadas con la trombina.
PT1083889E (pt) Compostos de tetra-hidronaftaleno e sua utilizacao no tratamento de doencas neurodegenerativas
ID30062A (id) Alanog-analog benzopiran tersubstitusi untuk pengobatan radang
ATE417602T1 (de) Mittel zur behandlung von erkrankungen der speiseröhre
CH1143977H1 (fr) 2-Oxy-benzoxazine-4-ones destinees au traitement de l'obesite
ATE310087T1 (de) Plasma-kallikrein inhibitoren vom kunitz-typ
NO994014D0 (no) Arylsulfonamider og analoger derav og deres anvendelse for behandling av neurodegenerative sykdommer
ATE247117T1 (de) Pyrazolopyrimidinone cgmp pde5 inhibitoren zur behandlung von sexualfunktionsstörungen
EP1311261A4 (fr) Medicaments pour le traitement chimiotherapeutique de maladies
FI943231A7 (fi) Ihmisen Kunitz-tyyppisen proteaasiestäjän muunnoksia
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
EP1126850A4 (fr) Traitement des affections de la retine
DE69807466D1 (de) Triptolid-derivate nützlich zur behandlung von autoimmunkrankheiten
EP1377287A4 (fr) Proanthocyanidines destinees au traitement des amyloses et des maladies induites par alpha-synucleine
DE60307086D1 (de) Zusammensetzng auf diclofenac-basis für die topische behandlung von erkrankungen des oropharynx
DZ3225A1 (fr) Methode et compositions pour le traitement des maladies pulmonaires
EE03437B1 (et) Benseenamiidid neurodegeneratiivsete haiguste ravimiseks
NO20004920D0 (no) Anvendelse av proteaseinhibitorer for behandling av hudskader
ATE251167T1 (de) Oxazinocarbazole zur behandlung von cns- erkrankungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20011024

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL;LT;LV;MK;RO;SI

A4 Supplementary search report drawn up and despatched

Effective date: 20020613

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

17Q First examination report despatched

Effective date: 20021022

17Q First examination report despatched

Effective date: 20021022

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

RTI1 Title (correction)

Free format text: TREATMENT OF NEURODEGENERATIVE DISORDERS USING ASPARTYL PROTEASE INHIBITORS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20071108